Shenzhen NewDEL Biotech Co., Ltd.
Project R & D
Core technology
As inspired by phage display,DNA-encoded library (DEL) technology combines the advantages of combinatorial chemistry and high throughput screening,which can efficiently discovery high-affinity small molecules against target proteins.
The DEL2.0 technology platform developed by NewDEL Biotech can be applied to live cell-based screening; This technology does not require the expression and purification of target proteins, and compared with the previous generation of biochemical models, the screening of DEL2.0 is closer to the real environment in vivo, thus making the screening success rate higher.SmartDEL Platform (DEL3.0) developed by NewDEL Biotech,integrates the latest Al technology with our DEL systems to provide a comprehensive one-stop solution for drug discovery and optimization. Our SmartDEL platform facilitates faster,more efficent lead generation and optimization processes.
NewDEL Biotech will continue to upgrade the new drug discovery technology platform around DEL technology, like DEL+protac,DEL+Macrocyclic Peptide,DEL+FBDD/SBDD and other characteristic new drug discovery technology platforms.
DEL 1.0 Technology
DEL2.0 Technology
Patent: CN20201 0213128
DEL3.O Technology (SmartDEL)
Publication:
1.Active Discovery Model: Front. Chem..2022,26:982539
2.Molecular Generation: Front. Pharma.2022,13:1085665
Shenzhen NewDEL Biotech Co., Ltd.
Contact: Mr. Lu Email：nd@newdel.com.cn
Telephone：+86-0755-28199301 Postal code： 518110
A1503 Building 1-A YESEN Intelligent Community,1301-76 Guanguang Rd.，Longhua Dist,Shenzhen,Guangdong,China
Copyright 2021-2022深圳市新樾生物科技有限公司版权所有 粤ICP备2022125782号
